Naringenin: A partial agonist on estrogen receptor in T47D-KBluc breast cancer cells

International Journal of Clinical and Experimental Medicine

Volumn 6, Issue 10, 2013, Pages 890-899

  Kim, Sunzoo ^a   Park, Tae In ^a  

^a Kyungpook National University Hospital   (South Korea)

Author keywords

Genistein; PS2; Selective estrogen receptor modulator; TGF 3

Indexed keywords

ESTRADIOL; ESTROGEN RECEPTOR BETA; GENISTEIN; LUCIFERASE; MESSENGER RNA; NARINGENIN; PROTEIN PS2; TRANSFORMING GROWTH FACTOR BETA3;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG POTENCY; ENZYME ACTIVITY; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; TRANSCRIPTION REGULATION;

EID: 84887686802     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Canderelli R, Leccesse LA, Miller NL and Unruh Davidson J. Benefts of hormone replacement therapy in postmenopausal women. J Am Acad Nurse Pract 2007; 19: 635-641.
2. Rymer J, Wilson R and Ballard K. Making decisions about hormone replacement therapy. BMJ 2003; 326: 322-326.
3. de Lignieres B, de Vathaire F, Fournier S, Urbi-nelli R, Allaert F, Le MG and Kuttenn F. Combined hormone replacement therapy and risk of breast cancer in a French cohort study of 3175 women. Climacteric 2002; 5: 332-340.
4. Cornwell T, Cohick W and Raskin I. Dietary phy-toestrogens and health. Phytochemistry 2004; 65: 995-1016.
5. Al-Azzawi F and Wahab M. Effectiveness of phytoestrogens in climacteric medicine. Ann N Y Acad Sci 2010; 1205: 262-267.
6. Koes R, Verweij W and Quattrocchio F. Flavo-noids: a colorful model for the regulation and evolution of biochemical pathways. Trends Plant Sci 2005; 10: 236-242.
7. Le Bail JC, Varnat F, Nicolas JC and Habrioux G. Estrogenic and antiproliferative activities on MCF-7 human breast cancer cells by favo-noids. Cancer Lett 1998; 130: 209-216.
8. Kuntz S, Wenzel U and Daniel H. Comparative analysis of the effects of favonoids on proliferation, cytotoxicity, and apoptosis in human colon cancer cell lines. Eur J Nutr 1999; 38: 133-142.
9. Meiyanto E, Hermawan A and Anindyajati. Natural products for cancer-targeted therapy: citrus favonoids as potent chemopreventive agents. Asian Pac J Cancer Prev 2012; 13: 427-436.
10. Bodet C, La VD, Epifano F and Grenier D. Nar-ingenin has anti-inflammatory properties in macrophage and ex vivo human whole-blood models. J Periodontal Res 2008; 43: 400-407.
11. Lee CH, Jeong TS, Choi YK, Hyun BH, Oh GT, Kim EH, Kim JR, Han JI and Bok SH. Anti-ath-erogenic effect of citrus favonoids, naringin and naringenin, associated with hepatic ACAT and aortic VCAM-1 and MCP-1 in high cholesterol-fed rabbits. Biochem Biophys Res Com-mun 2001; 284: 681-688.
12. Wang J, Yang Z, Lin L, Zhao Z, Liu Z and Liu X. Protective Effect of Naringenin Against Lead-Induced Oxidative Stress in Rats. Biol Trace Elem Res 2012; 146: 354-359.
13. Guo D, Wang J, Wang X, Luo H, Zhang H, Cao D, Chen L and Huang N. Double directional adjusting estrogenic effect of naringin from Rhi-zoma drynariae (Gusuibu). J Ethnopharmacol 2011; 138: 451-457.
14. Livak KJ and Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25: 402-408.
15. Matthews J and Gustafsson JA. Estrogen signaling: A subtle balance between ER alpha and ER beta. Mol Interv 2003; 3: 281-292.
16. Enmark E, Pelto-Huikko M, Grandien K, Lager-crantz S, Lagercrantz J, Fried G, Nordenskjold M and Gustafsson JA. Human estrogen receptor beta-gene structure, chromosomal localization, and expression pattern. J Clin Endocrinol Metab 1997; 82: 4258-4265.
17. Couse JF, Lindzey J, Grandien K, Gustafsson JA and Korach KS. Tissue distribution and quanti-tiative analysis of estrogen receptor-alpha (ERalpha) and estrogen receptor-beta (ERbe-ta) messenger ribonucleic acid in the wild-type and ERalpha-knock mouse. Endocrinology 1997; 138: 4613-4621.
18. Couse JF and Korach KS. Estrogen null mice: what have we learned and where will they lead us? Endocr Rev 1999; 20: 358-417.
19. Bourdeau V, Deschenes J, Laperriere D, Aid M, White JH and Mader S. Mechanisms of primary and secondary estrogen target gene regulation in breast cancer cells. Nucleic Acids Res 2008; 36: 76-93.
20. Pons M, Gagne D, Nicolas JC and Mehtali M. A new cellular model of response to estrogens: a bioluminescent test to characterize (anti) estrogen molecules. Biotechniques 1990; 9: 450-459.
21. Demirpence E, Duchesne MJ, Badia E, Gagne D and Pons M. MVLN cells: a bioluminescent MCF-7 derived cell line to study the modulation of estrogen activity. J Steroid Biochem Mol Biol 1993; 46: 355-364.
22. Wilson VS, Bobseine K and Gray LE. Development and characterization of a cell line that stably expresses an estrogen-responsive lucif-erase reporter for the detection of estrogen receptor agonist and antagonists. Toxicol Sci 2004; 81: 69-77.
23. Zierau O, Hamann J, Tischer S, Schwab P, Metz P, Vollmer G, Gutzeit HO and Scholz S. Narin-genin-type favonoids show different estrogen-ic effects in mammalian and teleost test systems. Biochem Biophys Res Commun 2005; 326: 909-916.
24. Ruh MF, Zacharewski T, Connor K, Howell J, Chen I and Safe S. Naringenin: a weakly estro-genic biofavonoid that exhibits antiestrogenic activity. Biochem Pharmacol 1995; 50: 1485-1493.
25. Zand RS, Jenkins DJ and Diamandis EP. Steroid hormone activity of favonoids and related compounds. Breast Cancer Res Treat 2000; 62: 35-49.
26. Taupin D, Wu DC, Jeon WK, Devaney K, Wang TC and Podolsky DK. The trefoil gene family are coordinately expressed immediate-early genes: EGF receptor- and MAP kinase-depen-dent interregulation. J Clin Invest 1999; 103: R31-R38.
27. Jorgensen M, Vendelbo B, Skakkebaek NE and Leffers H. Assaying estrogenicity by quantitat-ing the expression levels of endogenous estrogen-regulated genes. Environ Health Perspect 2000; 108: 403-412.
28. Knabbe C, Lippman ME, Wakefeld LM, Flanders KC, Kasid A, Derynck R and Dickson RB. Evidence that transforming growth factor-beta is a hormonally regulated negative growth factor in human breast cancer cells. Cell 1987; 48: 417-428.
29. Dannecker C, Possinger K and Classen S. Induction of TGF-beta by an antiprogestin in the human breast cancer cell line T-47D. Ann Oncol 1996; 7: 391-395.
30. Bates SE, Davidson NE, Valverius EM, Freter CE, Dickson RB, Tam JP, Kudlow JE, Lippman ME and Salomon DS. Expression of transforming growth factor alpha and its messenger ri-bonucleic acid in human breast cancer: its regulation by estrogen and its possible functional signifcance. Mol Endocrinol 1988; 2: 543-555.
31. So FV, Guthrie N, Chambers AF and Carroll KK. Inhibition of proliferation of estrogen receptor-positive MCF-7 human breast cancer cells by favonoids in the presence and absence of excess estrogen. Cancer Lett 1997; 112: 127-133.
32. Han DH, Denison MS, Tachibana H and Yama-da K. Relationship between estrogen receptor-binding and estrogenic activities of environmental estrogens and suppuression by favo-noids. Biosci Biotechnol Biochem 2002; 66: 1479-1487.